Mario Rodríguez
University of Concepción
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mario Rodríguez.
British Journal of Haematology | 2017
Carlos Montalbán; Antonio Díaz-López; Ivan Dlouhy; Jordina Rovira; Armando López-Guillermo; Sara Alonso; Alejandro Martín; Juan Manuel Sancho; Olga García; José María Chamoso Sánchez; Mario Rodríguez; Silvana Novelli; Antonio Salar; Antonio Gutierrez; María José Rodríguez-Salazar; Mariana Bastos; Juan F. Domínguez; Rubén Fernández; Sonia González de Villambrosia; José A. Queizán; Raúl Córdoba; Raquel de Oña; Andrés López-Hernández; Julián Matias Freue; Heidys Garrote; Lourdes López; Ana M. Martín-Moreno; José Leandro Tristán Rodríguez; Víctor Abraira; Juan F. García
The study included 1848 diffuse large B‐cell lymphoma (DLBCL)patients treated with chemotherapy/rituximab. The aims were to validate the National Comprehensive Cancer Network International Prognostic Index (NCCN‐IPI) and explore the effect of adding high Beta‐2 microglobulin (β2M), primary extranodal presentation and intense treatment to the NCCN‐IPI variables in order to develop an improved index. Comparing survival curves, NCCN‐IPI discriminated better than IPI, separating four risk groups with 5‐year overall survival rates of 93%, 83%, 67% and 49%, but failing to identify a true high‐risk population. For the second aim the series was split into training and validation cohorts: in the former the multivariate model identified age, lactate dehydrogenase, Eastern Cooperative Oncology Group performance status, Stage III‐IV, and β2M as independently significant, whereas the NCCN‐IPI‐selected extranodal sites, primary extranodal presentation and intense treatments were not. These results were confirmed in the validation cohort. The Grupo Español de Linfomas/Trasplante de Médula ósea (GELTAMO)‐IPI developed here, with 7 points, significantly separated four risk groups (0, 1–3, 4 or ≥5 points) with 11%, 58%, 17% and 14% of patients, and 5‐year overall survival rates of 93%, 79%, 66% and 39%, respectively. In the comparison GELTAMO IPI discriminated better than the NCCN‐IPI. In conclusion, GELTAMO‐IPI is more accurate than the NCCN‐IPI and has statistical and practical advantages in that the better discrimination identifies an authentic high‐risk group and is not influenced by primary extranodal presentation or treatments of different intensity.
Universum (talca) | 2009
Mario Rodríguez
Resumen es: Se propone que el “lenguaje hablado”, el tono oral empleado para narrar Los detectives salvajes, con los procedimientos propios de la oralidad, la elipsi...
Universum (talca) | 2014
Mario Rodríguez; Christian Troncoso
This article starts by developing a theoretical proposal on the notion of “detail” and how it functions in the short story of the 19th and early 20th centuri...
Revista Chilena De Literatura | 2008
Mario Rodríguez; José Manuel Rodríguez
Revista Chilena De Literatura | 1979
Mario Rodríguez
Revista Chilena De Literatura | 1984
Mario Rodríguez
Blood | 2017
Antonio Gutierrez; Leyre Bento; Carlos Montalbán; Antonio Díaz-López; Heidys Garrote; Julián Matias Freue; Lourdes López; Raquel de Oña; Ana Moreno; Armando López-Guillermo; Ivan Dlouhy; Jordina Rovira; Mario Rodríguez; José María Chamoso Sánchez; Monica Baile; Alejandro Martín; Silvana Novelli; Juan Manuel Sancho; Olga García; Antonio Salar; Mariana Bastos; María José Rodríguez-Salazar; Rubén Fernández; Juan F. Domínguez; José A. Queizán; Sonia González de Villambrosia; Raúl Córdoba; Víctor Abraira; Juan F. García; José Leandro Tristán Rodríguez
Revista Chilena De Literatura | 2016
Mario Rodríguez
Revista Chilena De Literatura | 2015
Mario Rodríguez
Blood | 2015
Carlos Montalbán; Antonio Díaz-López; Heidys Garrote Santana; Julián Matias Freue; Lourdes López; Raquel de Oña; Ana Moreno; Armando López-Guillermo; Ivan Dlouhi; Jordina Rovira; Mario Rodríguez; José Maria Sánchez Pina; Sara Alonso; Alejandro Garcia; Silvana Novelli; Juan-Manuel Sancho; Olga García; Antonio Salar; Antonio Gutierrez; Mariana Bastos; María José Rodríguez-Salazar; Rubén Ibernón Fernández; Juan F. Domínguez; José A. Queizán; Sonia González de Villambrosia; Raul Cordoba; Víctor Abraira; José Leandro Tristán Rodríguez; Juan F. García
Collaboration
Dive into the Mario Rodríguez's collaboration.
José Leandro Tristán Rodríguez
University of Texas MD Anderson Cancer Center
View shared research outputs